Abstract: The present invention refers to a composition comprising a conditioned cell culture medium obtained or obtainable by a process which comprises culturing a population of mesenchymal stromal cells (MSCs), in which at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, of said population by number of cells are MSCs obtained from a mammal pertaining to the genus Canis, in a nutrient rich liquid prepared for cell culture, preferably a basal media; and collecting the conditioned cell culture medium, wherein preferably the nutrient rich liquid is an animal/human serum-free media or a chemically defined animal/human serum-free and xeno free media designed to grow MSCs, for use in therapy.

Abstract: A process is incorporated herein for the synthesis of bio-1,2-alkanediols, comprising: providing a bio-alkene having a carbon chain of about 5 to about 20 carbon atoms and a bio-1-alkene regioselectivity of at least about 80%, at least about 92% and/or at least about 95%; and converting the bio-alkene to a bio-1,2-alkanediol having a carbon chain length of about 5 to about 20 carbon atoms. Methods for treating catalysts which may be incorporated in the process for the synthesis of bio-1,2-alkanediols are also included herein. Such bio-1,2-alkanediols are used in compositions and products alone as antimicrobial materials, or with existing bio-compounds and/or antimicrobials, preservatives, alternative preservation systems and/or hurdle technology components. The bio-1,2-alkanediols incorporate a natural and bio-based pathway for antimicrobial effects in various compositions such as cosmetic, pharmaceutical, industrial and household products.

Abstract: The present disclosure relates to non-comedogenic and hypoallergenic sunscreen compositions that comply with COSMOS-standard AISBL.

Abstract: The present invention relates to the use of natural protectants comprising (i) a cetylpyridinium salt (such as cetylpyridinium chloride) or p-anisic acid or a salt thereof (such as sodium p-anisate) and (ii) piroctone olamine to prevent microbial growth in a product, such as a personal care product.

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

Abstract: A hair treatment composition in a cationic system includes water and a novel association of polysaccharide, such as inulin, a wax, such as, candelilla wax, a cationic surfactant, such as, behentrimonium chloride, and a film-forming polymer, such as polysilicone-29. The composition may include one or more additional components selected from fatty compounds, cationic polymers and styling polymers, embodied to deliver one or more of smoothing, straightening and curling/curl defining style features to achieve a particular straight or curly style with frizz control, softness and manageability.

Abstract: The present invention relates to solid compositions for making up and/or caring for the skin and/or the lips, comprising at least one fatty phase comprising: —from 5 to 30% by weight of non volatile hydrocarbonated apolar oil(s), or mixture thereof, relative to the total weight of the composition, —from 43 to 90% by weight of total content of non volatile silicone oil(s) relative to the total weight of the composition, wherein at least one of said non volatile silicone oil(s) is a non volatile phenylated silicon oil, and—from 3 to 30% by weight of wax(es), or mixture thereof, relative to the total weight of the composition.

Abstract: The present invention concerns a composition comprising a Lycium barbarum extract or Lycium barbarum polysaccharide in combination with a Moringa oleifera extract and a pharmaceutically acceptable carrier. The composition finds application both in the medical field, in the treatment of actinic lesions, precancerous skin lesions, or non-melanoma skin cancer, and in non-therapeutic applications in the treatment of skin damage caused by exposure to the sun's rays, such as photoaging.

Abstract: The present disclosure relates to novel hydroxyl or halogen substituted derivatives of C11-C22 alkanoic acid ester of Paliperidone compound of formula (formula II) and process for preparing the same. The said compounds used in pharmaceutical composition for the treatment of schizophrenia and schizoaffective disorder, wherein, R?C10-C21 alkyl substituted by hydroxy or halogen.

Abstract: The present invention addresses a problem of providing a high quality seamless capsule, with excellent uniformity of shell thickness and virtually no eyes in the shell. The problem can be solved by manufacturing a seamless capsule using a shell composition comprising at least one polysaccharide selected from the group consisting of agar, carrageenan and gellan gum, and a PVA copolymer comprising the following structural units: (i) polyvinyl alcohol, (ii) at least one unsaturated carboxylic acid selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid and maleic acid, and (iii) at least one unsaturated carboxylic acid ester selected from the group consisting of compounds represented by formula [I]: H2C?C(R1)—COOR2??[I] (wherein R1 represents a hydrogen atom or a methyl group, and R2 represents an alkyl group having 1 to 4 carbon atoms).

Abstract: The present invention provides an emulsified cosmetic, including: an anionic acryl silicone copolymer (A) having an acryl chain as the main chain, the copolymer including, as monomer units, (I) 1 to 30% by mass of a polymerizable hydrophilic monomer having carboxylic acid, phosphoric acid, or sulfonic acid neutralized with a base, and (II) 10% by mass or more of a silicone macromonomer represented by the following general formula (1), or a silicone dendron group-containing polymerizable monomer; an oil material (B); and water (C). Accordingly, the present invention provides an emulsified cosmetic having excellent emulsification stability and non-stickiness.

Abstract: The disclosure provides methods of treating immunological conditions, e.g., allergy, by administration of berberine nanoparticles.

Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising: A) a backing layer; B) an asenapine-containing layer comprising: 1. asenapine in the form of the free base; and 2. a polymer selected from the group consisting of polysiloxanes and polyisobutylenes in an amount of more than 50% by weight based on the total weight of the asenapine-containing layer; and C) optionally an additional skin contact layer.

Abstract: Disclosed are personal care formulations, personal care methods and personal care devices that comprise or use a gel, lotion, cream or the like comprising (a) one or more active ingredients for providing a beneficial effect to the skin and/or hair and/or mucous membranes of a human and (b) from about 1 percent by weight to about 50 percent by weight of foam forming component(s) comprising trans-1-chloro-3,3,3-trifluoropropene (1233zd(E).

Abstract: Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.

Abstract: This disclosure is directed to compositions comprised of retinaldehyde, one or more skin conditioning agents, and, optionally, one or more additional retinoids. This disclosure is directed. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Additional embodiments disclose methods for treating the skin wherein a characteristic of the skin is improved, the characteristics include firmness, elasticity, fine lines and wrinkles, skin texture, dullness, dyschromia, skin tone, reduction or elimination of acne, and any combination thereof.

Abstract: The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

Abstract: Disclosed is a composition comprising a plurality of active botanical ingredients, each predominantly associated with an in-use beneficial effect on an animate or inanimate substrate, where said composition comprises: (i) a first aqueous extract of a material derived from a first plant, said first extract comprising a first amount of a first active botanical ingredient; (ii) a second aqueous extract of a material derived from a second plant whose genus is not the same as the first plant, said second extract comprising a first amount of a second active botanical ingredient; (iii) an additional amount of said first active botanical ingredient; and (iv) an additional amount of said second active botanical ingredient; where each said additional amount is included by spiking said composition or the corresponding aqueous extract selectively with said first and said second active botanical ingredients, such that ratio of said first amount of said first active botanical ingredient to its corresponding additional amou